Akt3 Modulation for Treg Immune Response Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current understanding of molecular pathways underlying regulatory T cell (Treg) activity is limited, and there is a need for therapeutics to modulate Treg activity for immune response management in conditions like autoimmunity and cancer.
Innovation Solution
Modulating Akt3 bioavailability using compounds such as inhibitory Akt3 polypeptides, small molecules, and nucleic acids to reduce or increase the immune suppressive or stimulating responses in subjects, thereby affecting natural and induced Treg functions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Akt3 bioavailability is increased to enhance Treg suppressive function, then immune homeostasis is improved, but anti-tumor immunity is inhibited
Solution Approach 1:
The patent applies local quality by using different Akt3 modulators in different tissue contexts: systemic Akt3 activation maintains peripheral immune homeostasis while localized Akt3 inhibition in tumor microenvironments preserves anti-tumor immunity. This spatially differentiated approach allows simultaneous optimization of both immune functions.
Solution Approach 2:
The patent segments the immune system into distinct compartments (peripheral tolerance vs. tumor immunity) and applies different Akt3 modulation strategies to each. Natural Tregs and induced Tregs are differentially regulated through isoform-specific approaches, allowing independent optimization of their functions.
2Object-affected harmful factors
If Akt3 activity is inhibited to reduce Treg suppressive function, then anti-tumor immunity is enhanced, but immune homeostasis is disrupted
Solution Approach 1:
The patent introduces Foxp3 as an intermediary marker to selectively identify and modulate Treg populations. By targeting Foxp3+ Tregs specifically with Akt3 inhibitors, the therapy enhances anti-tumor immunity while sparing other immune cells that maintain homeostasis, thus reducing systemic immune disruption.
Solution Approach 2:
The patent applies partial action by using selective Akt3 inhibition rather than complete blockade. Moderate inhibition levels are used to reduce Treg suppressive function in tumor environments while maintaining sufficient Akt3 activity elsewhere to preserve immune homeostasis and prevent autoimmunity.
3Ease of manufacture
If molecular pathways of Treg activity are better understood, then therapeutic targeting is improved, but research complexity increases
Solution Approach 1:
The patent extracts Akt3 as a specific molecular target from the complex PI3K-Akt signaling pathway. By focusing on this single isoform and its direct downstream effects on Treg function, the therapy simplifies the molecular targeting approach while maintaining therapeutic efficacy, avoiding the need to manipulate entire signaling cascades.
Data Source
AI summary
Methods of decreasing an immune suppressive response, increasing an immune stimulating response, or a combination thereof in a subject in need thereof are disclosed. The methods typically include administering the subject a composition including a compound that reduces the bioavailability of Akt3 in an amount effective to reduce the immune suppressive response, increase the immune stimulating response, or a combination thereof in the subject.Methods of increasing an immune suppressive response, decreasing an immune stimulating response, or a combination thereof in a subject in need thereof are also disclosed. The methods typically include administering the subject a composition including a compound that increases the bioavailability of Akt3 in an amount effective to increase the immune suppressive response, decrease the immune stimulating response, or a combination thereof in the subject.Pharmaceutical compositions, combination therapies and vaccine formulations including modulators of Akt3 bioactivity are also provided.